Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 4/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30024828 | 1.00 | KMT2A (0.54) | KMT2AHTTMEN1POLBMAPT | |
| Bromide SCHEMBL1254064 | 0.98 | KMT2A (0.52) | KMT2AHTTMEN1POLBMAPT | |
| SCHEMBL7934127 | 0.79 | KMT2A (0.54) | KMT2AHTTMEN1POLBMAPT | |
| SCHEMBL15052994 | 0.78 | TRIM24 (0.47) | KMT2AHTTERN1DYRK1ATRIM24 | |
| SCHEMBL28518576 | 0.77 | ERN1 (0.41) | KMT2AHTTERN1DYRK1ATRIM24 | |
| SCHEMBL24609208 | 0.75 | HTT (0.30) | KMT2AHTT | |
| SCHEMBL127596 | 0.75 | ERN1 (0.43) | HTTERN1IDO1MAP4K4 | |
| SCHEMBL124004 | 0.75 | ERN1 (0.39) | KMT2AHTTERN1MAP4K4ALDH1A1 | |
| SCHEMBL31056338 | 0.75 | ERN1 (0.39) | KMT2AHTTERN1MAP4K4ALDH1A1 | |
| SCHEMBL6856791 | 0.75 | HTT (0.30) | KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136906-A | Benzyl cyanide derivative and preparation method and application thereof | 湖南亚王医药科技有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-118359611-A | Imidazo [1,2-a ] pyridine derivative and preparation method and application thereof | 郑州大学 | 2024-07-19 | — | — | CN | claimed |
| CN-115835909-B | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4688768-A1 | NOVEL METTL3 INHIBITORS AND USE THEREOF IN THERAPY | Novalix (FR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4076460-B1 | 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025264700-A1 | GIP RECEPTOR AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12441730-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4605089-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | Mekanistic Therapeutics LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| CN-120136906-A | Benzyl cyanide derivative and preparation method and application thereof | 湖南亚王医药科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20060030583-A1 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| WO-2006015123-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1590339-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004069160-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069160-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-08-19 | — | — | WO | disclosed |
| EP-0946164-A4 | INTEGRIN ANTAGONISTS | MERCK & CO INC (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0946164-A1 | INTEGRIN ANTAGONISTS | Merck & Co., Inc. (US) | 1999-10-06 | — | — | EP | disclosed |
| US-5919792-A | Integrin antagonists | MERCK & CO., INC. (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1998018461-A1 | INTEGRIN ANTAGONISTS | MERCK & CO., INC. (US) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030583-A1 | Pyrrolo-pyridine kinase modulators | MAP3K20, MAP4K2, MAP3K19 | KMT2A 1322/4885HTT 2856/4885MEN1 4109/4885 |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GCGR | KMT2A 4611/4885HTT 1368/4885MEN1 3224/4885 |
| US-12441730-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | KMT2A 103/4885HTT 1340/4885MEN1 993/4885 |
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | KMT2A 3214/4885HTT 1075/4885MEN1 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.